Precipio Reports $0.3M cash generated by operations (unaudited) in Q2-2024, as the company advances towards breakeven
Precipio, Inc. (NASDAQ: PRPO), a specialty cancer diagnostics company, has reported $0.3M cash generated by operations (unaudited) in Q2-2024. This positive cash flow marks a significant milestone as the company advances towards breakeven. With cash reserves of approximately $1.3M at the end of Q2-2024 and a promising business pipeline, management is optimistic about reaching breakeven by year-end.
CEO Ilan Danieli expressed satisfaction with the company's progress, highlighting the transition away from structured deals that may harm shareholders. The improved cash position alleviates the need for capital raises in the foreseeable future, allowing Precipio to focus on building a strong base of long-term healthcare shareholders.
Precipio, Inc. (NASDAQ: PRPO), una compagnia specializzata nella diagnostica del cancro, ha riportato 0,3 milioni di dollari di liquidità generata dalle operazioni (non verificato) nel secondo trimestre del 2024. Questo flusso di cassa positivo segna una tappa significativa mentre l'azienda avanza verso il pareggio. Con riserve di liquidità di circa 1,3 milioni di dollari alla fine del secondo trimestre del 2024 e un promettente pipeline commerciale, la direzione è ottimista riguardo al raggiungimento del pareggio entro la fine dell'anno.
Il CEO Ilan Danieli ha espresso soddisfazione per i progressi dell'azienda, sottolineando la transizione lontano da accordi strutturati che potrebbero danneggiare gli azionisti. La posizione di cassa migliorata allevia la necessità di aumenti di capitale nel prossimo futuro, consentendo a Precipio di concentrarsi sulla creazione di una solida base di azionisti nel settore della salute a lungo termine.
Precipio, Inc. (NASDAQ: PRPO), una empresa especializada en diagnósticos de cáncer, ha reportado $0.3 millones en efectivo generado por operaciones (sin auditar) en el segundo trimestre de 2024. Este flujo de efectivo positivo marca un hito significativo a medida que la empresa avanza hacia el equilibrio. Con reservas de efectivo de aproximadamente $1.3 millones al final del segundo trimestre de 2024 y un prometedor pipeline de negocios, la dirección es optimista sobre alcanzar el equilibrio para fin de año.
El CEO Ilan Danieli expresó satisfacción con el progreso de la empresa, destacando la transición lejos de acuerdos estructurados que podrían perjudicar a los accionistas. La posición de efectivo mejorada alivia la necesidad de aumentar capital en el futuro cercano, permitiendo a Precipio enfocarse en construir una base sólida de accionistas en el sector de la salud a largo plazo.
프레시피오, Inc. (NASDAQ: PRPO), 암 진단 전문 회사는 2024년 2분기에 30만 달러의 운영에서 생성된 현금 (감사되지 않음)을 보고했습니다. 이 긍정적인 현금 흐름은 회사가 손익 분기점에 근접하고 있다는 중요한 이정표가 됩니다. 2024년 2분기 말 현재 약 130만 달러의 현금 보유고와 유망한 비즈니스 파이프라인을 보유하고 있어 경영진은 연말까지 손익 분기점에 도달할 수 있을 것으로 낙관하고 있습니다.
CEO 일란 다니엘리는 회사의 발전에 대한 만족을 표명하며, 주주들에게 해를 끼칠 수 있는 구조화된 거래에서의 전환을 강조했습니다. 개선된 현금 상황은 가까운 미래에 자본 증가의 필요성을 덜어주며, 프레시피오가 장기 건강 주주의 강력한 기반 구축에 집중할 수 있게 합니다.
Precipio, Inc. (NASDAQ: PRPO), une entreprise spécialisée dans le diagnostic du cancer, a rapporté 300 000 $ de liquidités générées par ses opérations (non audité) au deuxième trimestre de 2024. Ce flux de trésorerie positif marque une étape significative alors que l'entreprise progresse vers le seuil de rentabilité. Avec des réserves de liquidités d'environ 1,3 million de dollars à la fin du deuxième trimestre 2024 et un pipeline commercial prometteur, la direction est optimiste concernant l'atteinte du seuil de rentabilité d'ici la fin de l'année.
Le PDG Ilan Danieli a exprimé sa satisfaction quant aux progrès de l'entreprise, soulignant la transition loin des accords structurés qui pourraient nuire aux actionnaires. La position de trésorerie améliorée allège le besoin de levées de fonds dans un avenir proche, permettant à Precipio de se concentrer sur la construction d'une base solide d'actionnaires de santé à long terme.
Precipio, Inc. (NASDAQ: PRPO), ein spezialisiert auf Krebsdiagnostik Unternehmen, hat im 2. Quartal 2024 0,3 Millionen US-Dollar aus dem operativen Geschäft (nicht geprüft) gemeldet. Dieser positive Cashflow markiert einen bedeutenden Meilenstein, während das Unternehmen sich dem Break-even nähert. Mit Bargeldreserven von etwa 1,3 Millionen US-Dollar Ende des 2. Quartals 2024 und einer vielversprechenden Geschäftsperspektive ist das Management optimistisch, bis zum Jahresende den Break-even zu erreichen.
CEO Ilan Danieli äußerte Zufriedenheit mit dem Fortschritt des Unternehmens und hob die Abkehr von strukturierten Vereinbarungen hervor, die den Aktionären schaden könnten. Die verbesserte Kassensituation verringert die Notwendigkeit von Kapitalerhöhungen in naher Zukunft und ermöglicht es Precipio, sich auf den Aufbau einer soliden Basis von langfristigen Gesundheitsaktionären zu konzentrieren.
- $0.3M cash generated from operations in Q2-2024
- Cash reserves of $1.3M at the end of Q2-2024
- Advancing towards breakeven, potentially by year-end
- Reduced need for dilutive transactions or capital raises
- None.
Insights
Precipio's Q2-2024 unaudited results show a positive shift in the company's financial trajectory. The $0.3M cash generated from operations marks a significant milestone, especially for a specialty diagnostics company in the growth phase. This improvement in cash flow is a strong indicator of operational efficiency and revenue growth.
The company's cash reserves of
Key points to consider:
- The positive cash flow includes delayed Q1 collections due to the Change Healthcare hack, which may have inflated the Q2 figure.
- The company's ability to generate cash without resorting to dilutive financing is a positive sign for shareholder value.
- The focus on building a strong base of long-term healthcare shareholders could lead to more stable stock performance in the future.
While the news is promising, investors should monitor future quarters to confirm if this positive trend continues and if the company indeed reaches breakeven as projected.
As a specialty cancer diagnostics company, Precipio's financial improvement could have significant implications for its research and development capabilities. The positive cash flow suggests that the company may be gaining traction in the competitive cancer diagnostics market.
Key considerations from a medical research perspective:
- Improved financial health could potentially lead to increased investment in R&D, enhancing Precipio's diagnostic technologies and expanding its product pipeline.
- The company's focus on efficiency while growing the business may translate to more cost-effective diagnostic solutions, which is important in the healthcare sector.
- Reaching financial stability could attract more partnerships and collaborations within the medical community, potentially accelerating the development and adoption of Precipio's diagnostic tools.
However, it's important to note that the announcement doesn't provide specific details about the company's product performance or market penetration. Investors and healthcare professionals should look for future updates on Precipio's diagnostic offerings and their clinical impact to fully assess the company's progress in the cancer diagnostics field.
Company’s continued growth and improved cash position alleviates the need for capital raise in the foreseeable future
NEW HAVEN, Conn., July 25, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that its unaudited non-GAAP Cash Burn/Generated from Operations (CBFO) for Q2-2024 was
With cash reserves of approximately
“It’s great to see the fruits of our work translate into cash flow. I am hopeful that gone are the days where the company needs to conduct structured deals that harm shareholders and place the company’s equity in the hands of investors that don't have the company’s long-term interests in mind. Our team has worked hard to effectively and efficiently grow the business, while conserving every dollar to ensure that there should be no need for additional dilutive transactions in the foreseeable future,” said Ilan Danieli, CEO. “It’s time our company stands on its own two feet financially, and builds a strong base of individual & institutional healthcare shareholders, ones that have a long-term perspective, with the company’s success, growth and shareholder value appreciation in mind.”
About Precipio
Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis. For more information, please visit www.precipiodx.com.
Please follow us on LinkedIn, Twitter @PrecipioDx and on Facebook.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the targets set herein and related timing.
Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, Quarterly Report on Form 10-Q for the three months ended March 31, 2024, and our other reports filed with the U.S. Securities and Exchange Commission. Any such forward-looking statements represent management’s estimates as of the date of this press release only. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
FAQ
What was Precipio's (PRPO) cash generated from operations in Q2-2024?
What are Precipio's (PRPO) cash reserves as of Q2-2024?
When does Precipio (PRPO) expect to reach breakeven?
How has Precipio's (PRPO) improved cash position affected its need for capital raises?
